Infraredx

The PROSPECT II study was published in the March 13th issue of The Lancet,
finding that IVUS+NIRS imaging can detect plaques at increased risk for future adverse cardiac outcomes.VIEW ARTICLE VIEW ARTICLE

Together, we are fighting
Coronary Artery Disease
because the heart is everything.

WATCH VIDEO

Reduce blood loss with the OKAY® II Y-Connector

NOW AVAILABLE IN THE USA
#1 selling Y-Connector in Japan

View Product Details Start a Free Trial

Infraredx, a Nipro Company, and B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc., Announce Strategic U.S. Collaboration to Execute the IDE Clinical Trial for the SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter.

Now FDA indicated to identify plaque and patients at increased risk of MACE.

Achieve unparalleled insights with the Makoto™ Imaging System and its accompanying Dualpro™ IVUS + NIRS catheter, the only FDA-cleared dual-modality catheter and imaging system indicated for the identification of patients and plaques at increased risk of major adverse cardiac events (MACE).